1 |
NCT03317340 |
Not yet recruiting |
Environmental Factors to Increase Patient Comfort During Urodynamics Testing |
- Lower Urinary Tract Symptoms
- Urologic Diseases
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comfort level with test based off post-urodynamic survey
|
200 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03317340 |
17-003351 |
|
March 14, 2018 |
March 1, 2019 |
April 1, 2019 |
October 23, 2017 |
January 23, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
2 |
NCT01887574 |
Recruiting |
Renal Mass Registry |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Evidence of Renal Mass Risk Factors as determined by patient questionnaire post surgery
|
5000 |
All |
18 Years and older (Adult, Senior) |
NCT01887574 |
13-002688 |
|
June 2013 |
June 2053 |
June 2053 |
June 27, 2013 |
January 15, 2016 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
3 |
NCT03299387 |
Recruiting |
INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI |
|
- Drug: Nitrofurantoin
- Drug: Gentamicin
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in microbiologic effect of a chronic acute Urinary Tract Infection
- Change in symptomatic relief of a chronic acute Urinary Tract Infection
- To establish the clinical FTE needs for providing urgent intravesical treatments
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT03299387 |
11-002887 |
INSTANT |
June 28, 2017 |
July 1, 2019 |
July 14, 2019 |
October 3, 2017 |
October 3, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
4 |
NCT01359046 |
Recruiting |
Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology |
- Infection Associated With Catheter
- Urinary Tract Infection
|
- Device: silver SPC
- Device: standard SPC
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- UTI rate
- Medical treatment of UTI symptoms
|
444 |
Female |
18 Years and older (Adult, Senior) |
NCT01359046 |
10-007421 |
|
July 2011 |
March 2018 |
March 2018 |
May 24, 2011 |
August 8, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
5 |
NCT03281798 |
Recruiting |
Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO) |
- Congenital Disorders
- Bilateral Hydronephrosis
- Lower Urinary Tract Obstructive Syndrome
|
- Device: Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
|
Interventional |
Not Applicable |
- Rodrigo Ruano M.D., Ph.D
- Mayo Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Number of successfully completed surgical procedures
|
10 |
Female |
18 Years and older (Adult, Senior) |
NCT03281798 |
16-008556 |
LUTO |
January 1, 2018 |
December 31, 2020 |
July 31, 2021 |
September 13, 2017 |
January 9, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
6 |
NCT02848131 |
Recruiting |
Senescence in Chronic Kidney Disease |
|
- Drug: Group 2: Dasatinib
- Drug: Group 2: Quercetin
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in proportion of senescent cells (representing the total senescent cell burden) present
- Change in proportion of senescent mesenchymal stem cells present
- Change in mesenchymal stem cell function
- (and 2 more...)
|
20 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02848131 |
15-005843 |
|
July 2016 |
April 2020 |
May 2021 |
July 28, 2016 |
January 5, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
7 |
NCT01893658 |
Recruiting |
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN) |
- Acute Interstitial Nephritis
|
- Drug: Omalizumab
- Drug: Prednisone
|
Interventional |
Phase 2 |
- Mayo Clinic
- Genentech, Inc.
- Mayo Clinic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in serum creatinine
- Mean individual percentage drop in serum creatinine relative to entry creatinine levels
- Percentage of subjects returning to their usual baseline creatinine (+25%) or below
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01893658 |
12-006797 |
|
June 1, 2018 |
September 2018 |
December 2018 |
July 9, 2013 |
February 23, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
8 |
NCT01568918 |
Recruiting |
Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery |
- Postoperative Urinary Retention
|
- Drug: Tamsulosin hydrochloride
- Other: Placebo
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Incidence of postoperative urinary retention
- Duration of postoperative urinary retention
|
350 |
All |
35 Years and older (Adult, Senior) |
NCT01568918 |
11-006704 |
|
May 2012 |
December 2018 |
December 2018 |
April 2, 2012 |
November 9, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
9 |
NCT02838667 |
Recruiting |
Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI) |
- Acute Renal Injury
- Preventive Measures
|
- Procedure: Standard of Care plus Nephrology Care
|
Interventional |
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Perfusion pressures (mean arterial pressure) ≥ 65-70 mmHg
|
2300 |
All |
18 Years and older (Adult, Senior) |
NCT02838667 |
16-003845 |
|
July 2016 |
June 2017 |
August 2017 |
July 20, 2016 |
July 22, 2016 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
10 |
NCT02773849 |
Recruiting |
A Study to Evaluate INSTILADRIN® in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC |
- Superficial Bladder Cancer
|
|
Interventional |
Phase 3 |
- FKD Therapies Oy
- Society of Urologic Oncology Clinical Trials Consortium
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the complete response rate in patients with Carcinoma in situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.
- To evaluate the durability of complete response in patients with CIS (with or without concomitant Ta or T1 papillary disease) who achieve a complete response.
- To evaluate the rate of event-free survival, where event-free survival is defined as high-grade recurrence free survival in patients with high-grade Ta or T1 disease (without concomitant CIS)
- (and 6 more...)
|
135 |
All |
18 Years and older (Adult, Senior) |
NCT02773849 |
rAd-IFN-CS-003 |
|
September 2016 |
June 2019 |
June 2022 |
May 16, 2016 |
April 12, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Keck School of Medicine at USC Medical Center
Los Angeles, California, United States - The Urology Center of Colorado
Denver, Colorado, United States - (and 31 more...)
|
11 |
NCT03236103 |
Not yet recruiting |
AKI Prevention and Early Intervention in VAD Patients Admitted for Acute Medical Events. |
|
- Other: Clinical Recommendations
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of AKI in hospitalized VAD patients based on AKIN criteria
- Severity of AKI based on AKIN stages (I, II, III) 1
- Length of hospital stay
- In hospital, 60 day and one-year mortality
|
900 |
All |
18 Years and older (Adult, Senior) |
NCT03236103 |
17-002670 |
|
August 1, 2017 |
August 30, 2018 |
August 30, 2018 |
August 1, 2017 |
August 1, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
12 |
NCT03182998 |
Recruiting |
Decision Aids to Improve Knowledge in Patients With Prostate Cancer |
|
- Other: Internet-Based Intervention
- Other: Best Practice
- Other: Quality-of-Life Assessment
- (and 3 more...)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Knowledge assessed by Prostate Cancer Treatment questionnaire
- Decisional quality as measured by Decisional Conflict Scale Decisional Regret
- Quality of life assessed by questionnaire
- Utilization as determined by chart review
|
100 |
Male |
18 Years and older (Adult, Senior) |
NCT03182998 |
16-010459 |
|
July 14, 2017 |
January 1, 2020 |
January 1, 2020 |
June 9, 2017 |
September 6, 2017 |
|
- Alaska Native Tribal Health Consortium
Anchorage, Alaska, United States - University Hospitals Case Medical Center
Cleveland, Ohio, United States - Metrohealth Medical Center Urology Institute
Cleveland, Ohio, United States - Regional Health
Rapid City, South Dakota, United States
|
13 |
NCT02058095 |
Recruiting |
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3) |
- Cardiomyopathy
- Renal Impairment
|
- Drug: Tadalafil
- Drug: Placebo
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in urinary sodium excretion
- Change in Glomerular Filtration Rate (GFR)
|
45 |
All |
21 Years to 90 Years (Adult, Senior) |
NCT02058095 |
11-006194 HL76611-07P3 |
Aim 3 |
March 2014 |
March 2018 |
June 2018 |
February 7, 2014 |
August 28, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
14 |
NCT01970176 |
Recruiting |
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2) |
- Cardiomyopathy
- Renal Impairment
|
- Drug: Tadalafil
- Drug: Placebo
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Na excretion
- Change in GFR from baseline
- Change in urinary cGMP excretion
|
45 |
All |
21 Years to 90 Years (Adult, Senior) |
NCT01970176 |
11-004644 HL76611-07P3 |
Aim2 |
November 2013 |
March 2018 |
May 2018 |
October 25, 2013 |
August 28, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
15 |
NCT03493802 |
Recruiting New |
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD |
- Autosomal Dominant Polycystic Kidney Disease
|
|
Observational |
|
- Mayo Clinic
- University of Kansas Medical Center
- Mayo Clinic
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Assessment of endothelial function by Peripheral Artery Tonometry (PAT)
- NADPH oxidase 4 (NOX4) expression/activity
- Mitochondrial DNA copy number
- (and 3 more...)
|
27 |
All |
18 Years to 40 Years (Adult) |
NCT03493802 |
17-005944 |
|
November 1, 2017 |
November 1, 2019 |
November 1, 2020 |
April 11, 2018 |
April 11, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
16 |
NCT03095118 |
Recruiting |
Daratumumab in Treatment of PGNMID and C3 GN |
- Membranoproliferative Glomerulonephritis
|
|
Interventional |
Phase 2 |
- Fernando Fervenza
- Mayo Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events
- Kidney Function
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03095118 |
16-004805 |
|
September 7, 2017 |
September 2019 |
December 2019 |
March 29, 2017 |
October 11, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
17 |
NCT03305835 |
Recruiting |
Monogenic Kidney Stone - Genetic Testing |
- Rare Kidney Stone Diseases
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- symptomatic onset of monogenic stone disease
- Genotype markers
|
2300 |
All |
Child, Adult, Senior |
NCT03305835 |
17-005513 |
|
September 11, 2017 |
December 2020 |
December 2020 |
October 10, 2017 |
March 23, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
18 |
NCT02016235 |
Recruiting |
Role Of Phosphorus And FGF 23 In Patients With Dent Disease |
|
- Drug: Phosphorus Supplement
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in 24 hr urine and serum after 2 weeks of phosphorus supplementation
|
40 |
Male |
18 Years and older (Adult, Senior) |
NCT02016235 |
13-004774 |
|
September 2014 |
June 2018 |
June 2018 |
December 19, 2013 |
August 7, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
19 |
NCT01901094 |
Recruiting |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
|
- Procedure: Axillary Lymph Node Dissection (ALND)
- Radiation: Nodal Radiation Therapy
- Radiation: Axillary Radiation Therapy
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive breast cancer recurrence-free interval (IBC-RFI)
- Overall survival
- Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)
|
2918 |
All |
18 Years and older (Adult, Senior) |
NCT01901094 |
A011202 U10CA031946 NCI-2013-00875 |
|
February 2014 |
January 2024 |
|
July 17, 2013 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1091 more...)
|
20 |
NCT01783795 |
Recruiting |
Dent Disease Mutation Genotyping |
|
- Genetic: Genetic Analysis
|
Interventional |
Not Applicable |
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Mayo Clinic
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Number of subjects with genetic mutations in either the CLCN5 or ORCL1 gene
|
180 |
All |
Child, Adult, Senior |
NCT01783795 |
10-006442 U54DK083908 |
|
August 2012 |
June 2018 |
June 2018 |
February 5, 2013 |
June 20, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
21 |
NCT03180723 |
Not yet recruiting |
Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis |
- Membranoproliferative Glomerulonephritis
|
- Drug: Rituximab
- Drug: Cyclosporin
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- effect of Rituximab on proteinuria
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03180723 |
RMPGN |
|
July 1, 2017 |
July 2019 |
December 2019 |
June 8, 2017 |
June 16, 2017 |
|
|
22 |
NCT02171429 |
Recruiting |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2) |
|
- Drug: Adalimumab
- Other: Adalimumab Placebo
- Drug: Etrolizumab
- Other: Etrolizumab Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Induction of Remission Compared With Placebo as Determined by the Mayo Clinic Score (MCS)
- Percentage of Participants With Induction of Remission Compared With Adalimumab as Determined by the MCS
- Percentage of Participants With Induction of Clinical Remission as Determined by the MCS
- (and 12 more...)
|
350 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02171429 |
GA28949 2013-004277-27 |
|
November 14, 2014 |
October 30, 2020 |
October 30, 2020 |
June 24, 2014 |
April 2, 2018 |
|
- Community Clinical Trials
Orange, California, United States - Digestive Care Associates, A Medical Corporation
San Carlos, California, United States - Medical Associates Research Group, Inc.
San Diego, California, United States - (and 153 more...)
|
23 |
NCT02026388 |
Recruiting |
Rare Kidney Stone Consortium Biobank |
- Primary Hyperoxaluria
- Dent Disease
- APRT Deficiency
- Cystinuria
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of samples stored in tissue bank
|
400 |
All |
Child, Adult, Senior |
NCT02026388 |
11-005413 |
|
May 2013 |
June 2020 |
June 2020 |
January 3, 2014 |
August 4, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
24 |
NCT02340689 |
Recruiting |
Primary Hyperoxaluria Mutation Genotyping/Phenotyping |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Genotype markers of early symptomatic onset of primary hyperoxaluria
- Genotype markers of marked hyperoxaluria in patients with primary hyperoxaluria
- Genotype markers of early loss of kidney function in patients with primary hyperoxaluria.
|
1250 |
All |
Child, Adult, Senior |
NCT02340689 |
13-006384 |
|
October 2013 |
December 2020 |
December 2020 |
January 19, 2015 |
August 7, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
25 |
NCT02808208 |
Recruiting |
Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure |
- End Stage Renal Disease (ESRD)
- Vascular Access Complication
|
- Biological: Adipose Derived Mesenchymal Stem Cells (AMSC)
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Hemodialysis outflow vein diameter
- Hemodialysis AVF Blood flow
|
44 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02808208 |
15-009053 |
|
June 7, 2017 |
July 2018 |
July 2019 |
June 21, 2016 |
August 21, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
26 |
NCT03325322 |
Recruiting |
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease |
- Chronic Kidney Diseases
- Diabetes Mellitus
- Diabetic Nephropathies
|
- Dietary Supplement: Fisetin
- Drug: Placebo oral capsule
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in inflammatory markers including C-reactive protein
- Effect on Mesenchymal stem cell function including cell migration
- Effect on measures of Frailty including Fried Criteria
- (and 5 more...)
|
30 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT03325322 |
16-010521 |
|
January 2, 2018 |
January 2021 |
April 2022 |
October 30, 2017 |
January 5, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
27 |
NCT02554253 |
Recruiting |
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction |
- Cognitive Disorders
- Delirium
- Acute Kidney Injury
|
- Drug: Ketamine
- Drug: Propofol
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of patients with postoperative cognitive dysfunction
- Number of patients with acute kidney injury
- Number of patients who develop postoperative delirium
|
52 |
All |
75 Years and older (Senior) |
NCT02554253 |
14-007148 |
|
September 2015 |
December 2018 |
December 2018 |
September 18, 2015 |
February 28, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
28 |
NCT00588562 |
Recruiting |
Rare Kidney Stone Consortium Patient Registry |
- Primary Hyperoxaluria
- Dent Disease
- Cystinuria
- APRT Deficiency
|
|
Observational |
|
- Mayo Clinic
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- Establish and expand registries and collaborate with patient organizations for the rapid dissemination of knowledge
- Improved understanding of symptoms and progression of four major diseases of hereditary nephrolithiasis.
|
730 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT00588562 |
11-001702 1U54DK083908-01 |
RKSC |
July 2003 |
June 2019 |
June 2019 |
January 8, 2008 |
August 4, 2017 |
|
- Dent Disease Registry -Mayo Clinic
Rochester, Minnesota, United States - Primary Hyperoxaluria Registry - Mayo Clinic
Rochester, Minnesota, United States - Cystinuria Registry - New York University
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
29 |
NCT02266394 |
Recruiting |
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension |
- Renal Artery Stenosis
- Ischemic Nephropathy
- Renovascular Disease
- Chronic Kidney Disease
|
- Drug: Mesenchymal stem cell
- Procedure: Mesenchymal stem cell delivery with stent placement
|
Interventional |
Phase 1 |
- Mayo Clinic
- University of Mississippi Medical Center
- University of Alabama at Birmingham
- Mayo Clinic
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Kidney function
- Safety of Mesenchymal stem cell infusion
- Decrease in Kidney inflammation
|
42 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02266394 |
14-002799 |
|
October 2014 |
March 2019 |
March 2019 |
October 17, 2014 |
August 7, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - Mayo Clinic
Rochester, Minnesota, United States - University of Mississippi
Jackson, Mississippi, United States
|
30 |
NCT02780297 |
Recruiting |
Prospective Research Rare Kidney Stones (ProRKS) |
- Hyperoxaluria
- Cystinuria
- Dent Disease
- (and 2 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- inflammatory blood and urinary biomarkers
- Longitudinal changes in eGFR
|
220 |
All |
Child, Adult, Senior |
NCT02780297 |
16-000494 |
ProRKS |
May 2016 |
July 2024 |
July 2024 |
May 23, 2016 |
October 10, 2017 |
|
- University of Alabama @ Birmingham
Birmingham, Alabama, United States - Mayo Clinic Jacksonville
Jacksonville, Florida, United States - Children's Memorial Hospital
Chicago, Illinois, United States - (and 8 more...)
|
31 |
NCT02152137 |
Recruiting |
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer |
- Anaplastic Thyroid Cancer
- Recurrent Thyroid Cancer
|
- Drug: efatutazone
- Drug: paclitaxel
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Daiichi Sankyo, Inc.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed response rate (partial response [PR] or complete response [CR]) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
- Overall Survival
- Duration of confirmed response
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02152137 |
A091305 U10CA031946 U10CA180821 NCI-2014-00686 |
|
September 2014 |
July 2019 |
|
June 2, 2014 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 230 more...)
|
32 |
NCT03178435 |
Recruiting |
Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score |
- Acute Kidney Injury
- Critical Illness
|
- Other: Measures to prevent AKI among critically ill patients
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of AKI
- 30 day mortality
- Time to recovery after development of AKI
- (and 2 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT03178435 |
KA-13050 |
PRAIOC-RISKS |
September 1, 2017 |
March 1, 2018 |
July 1, 2018 |
June 7, 2017 |
October 10, 2017 |
|
- Cairo university hospitals
Cairo, Egypt
|
33 |
NCT03219333 |
Recruiting |
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer |
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- (and 4 more...)
|
|
Interventional |
Phase 2 |
- Astellas Pharma Global Development, Inc.
- Seattle Genetics, Inc.
- Astellas Pharma Inc
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) by an independent review facility (IRF)
- Duration of response (DOR) by an IRF
- Disease control rate at 16 weeks (DCR16) by an IRF
- (and 13 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03219333 |
SGN22E-001 |
EV-201 |
September 20, 2017 |
September 2019 |
March 2024 |
July 17, 2017 |
April 17, 2018 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States - University of California Davis
Davis, California, United States - (and 41 more...)
|
34 |
NCT03404791 |
Recruiting |
Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy |
- Bladder Cancer TNM Staging Primary Tumor (T) T2A
- Bladder Cancer TNM Staging Primary Tumor (T) T2B
- Bladder Cancer TNM Staging Primary Tumor (T) T3A
- Bladder Cancer TNM Staging Primary Tumor (T) T3B
|
- Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with incidence of treatment emergent adverse events (TEAEs) over 4 consecutive 21-day dosing cycles of TAR-200 as assessed by CTCAE V4.0
- Number of participants that do not require TAR-200 removal prior to the scheduled date of removal due to meeting any of the Subject Stopping Safety Criteria or other drug or device related AE
- Proportion of subjects with clinical complete response (cCR)
- (and 8 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT03404791 |
TAR-200-103 |
|
December 15, 2017 |
July 2018 |
May 2019 |
January 19, 2018 |
April 5, 2018 |
|
- Mayo Clinic
Phoenix, Arizona, United States - North Georgia Urology
Dalton, Georgia, United States - Chesapeake Urology
Hanover, Maryland, United States - (and 6 more...)
|
35 |
NCT03024996 |
Recruiting |
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy |
|
- Drug: Atezolizumab
- Other: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IRF-assessed Disease-Free Survival (DFS)
- Overall Survival
- Investigator-assessed DFS
- (and 10 more...)
|
664 |
All |
18 Years and older (Adult, Senior) |
NCT03024996 |
WO39210 2016-001881-27 |
IMmotion010 |
January 3, 2017 |
May 24, 2022 |
April 13, 2024 |
January 19, 2017 |
April 10, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Mayo Clinic- Scottsdale
Scottsdale, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - (and 223 more...)
|
36 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1211 more...)
|
37 |
NCT03350269 |
Recruiting |
Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates |
- Kidney Failure
- Surgery
- Renal Failure
|
- Other: Information provision
|
Interventional |
Not Applicable |
- Arbor Research Collaborative for Health
- Laura and John Arnold Foundation
- American Society of Transplant Surgeons
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Effect of offering wage reimbursement on rate of living donor kidney transplant
- Difference in time to outcome events (living donor transplant, deceased donor transplant, removal from transplant waiting list, death) between control group and intervention arm
- Effect of offering donor wage reimbursement on demographic characteristics of living kidney donor pool
|
2750 |
All |
18 Years and older (Adult, Senior) |
NCT03350269 |
Kidney Donor Lost Wages Study |
|
November 15, 2017 |
May 2019 |
June 2020 |
November 22, 2017 |
March 9, 2018 |
|
- University of Colorado
Denver, Colorado, United States - Michigan Medicine - University of Michigan
Ann Arbor, Michigan, United States - University of Minnesota
Minneapolis, Minnesota, United States - Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
38 |
NCT01515787 |
Recruiting |
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery |
|
- Drug: FOLFOX (chemotherapy)
- Other: 5 FUCMT (chemoradiation)
- Procedure: surgery
- Procedure: magnetic resonance imaging or endorectal ultrasound
|
Interventional |
Phase 2 Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic R0 resection rate (Phase II)
- DFS (Phase III)
- Time to local recurrence (TLR)
- (and 4 more...)
|
1120 |
All |
18 Years and older (Adult, Senior) |
NCT01515787 |
N1048 CDR0000715321 NCI-2012-00234 U10CA031946 |
|
January 2012 |
January 2021 |
|
January 24, 2012 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1030 more...)
|
39 |
NCT02912559 |
Recruiting |
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
- Colon Adenocarcinoma
- DNA Repair Disorder
- Lynch Syndrome
- (and 4 more...)
|
- Drug: Atezolizumab
- Drug: Fluorouracil
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival (DFS)
- Overall survival
- Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0
|
700 |
All |
18 Years and older (Adult, Senior) |
NCT02912559 |
NCI-2016-01417 A021502 U10CA180821 |
|
September 12, 2017 |
July 1, 2020 |
July 1, 2020 |
September 23, 2016 |
April 19, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 700 more...)
|
40 |
NCT02750826 |
Recruiting |
Breast Cancer WEight Loss Study (BWEL Study) |
|
- Other: Health Education Program
- Other: Weight Loss Intervention
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Division of Cancer Control
- NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival
- Overall survival
- Distant disease-free survival
- (and 20 more...)
|
3136 |
Female |
18 Years and older (Adult, Senior) |
NCT02750826 |
A011401 NCI-2015-01918 |
|
August 2016 |
May 2030 |
|
April 26, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1259 more...)
|
41 |
NCT02201992 |
Recruiting |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
378 |
All |
18 Years and older (Adult, Senior) |
NCT02201992 |
E4512 NCI-2014-01507 s16-02072 U10CA180820 U10CA180830 U10CA021115 U24CA196172 |
|
August 18, 2014 |
May 1, 2022 |
|
July 28, 2014 |
December 11, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1286 more...)
|
42 |
NCT02194738 |
Recruiting |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- (and 9 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- National Cancer Institute (NCI)
|
NIH |
|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis, as measured by adequate specimens collected per month
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping
|
8300 |
All |
18 Years and older (Adult, Senior) |
NCT02194738 |
NCI-2014-01509 A151216 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
September 28, 2021 |
September 28, 2021 |
July 18, 2014 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1330 more...)
|
43 |
NCT02193282 |
Recruiting |
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Placebo
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS) rate, defined as the proportion of patients alive and disease free at 2 years from the date of randomization
- Overall survival (OS) rate defined as the proportion of patients alive at 5 years from date of randomization
- (and 3 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT02193282 |
NCI-2014-01508 s16-02079 CALGB A081105 A081105 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
November 4, 2020 |
|
July 17, 2014 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1302 more...)
|
44 |
NCT02793128 |
Recruiting |
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study |
- Carcinoma, Transitional Cell
|
- Drug: MitoGel™ instillations
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response (CR) Rate defined as percent of patients with CR at the Primary Disease Evaluation (PDE) Visit
- Adverse events rate
- Long Term Durability of Complete Response (CR)
- (and 3 more...)
|
74 |
All |
18 Years and older (Adult, Senior) |
NCT02793128 |
TC-UT-03-P |
Olympus |
April 4, 2017 |
December 2018 |
January 2020 |
June 8, 2016 |
April 18, 2018 |
|
- Alaska Urological Institute
Anchorage, Alaska, United States - Mayo Clinic Hospital
Phoenix, Arizona, United States - University of California
Davis, California, United States - (and 30 more...)
|
45 |
NCT02927249 |
Recruiting |
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
- Node Positive HER2 Negative Breast Cancer
|
- Other: Placebo
- Drug: Aspirin
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- United States Department of Defense
- Bayer
|
Other / NIH / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (iDFS)
- Overall survival (OS)
- Distant disease free survival (DDFS)
- (and 2 more...)
|
2936 |
All |
18 Years to 69 Years (Adult, Senior) |
NCT02927249 |
A011502 NCI-2016-00233 U10CA180821-01 |
|
December 2016 |
April 2021 |
|
October 7, 2016 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1176 more...)
|
46 |
NCT01674140 |
Recruiting |
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
- Drug: anastrozole
- Drug: everolimus
- Drug: exemestane
- (and 5 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IDFS using a stratified log-rank test, assessed up to 10 years
- OS estimates will be based on Kaplan-Meier procedures, assessed up to 10 years
- DRFS, assessed up to 10 years
- Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, assessed up to 10 years
|
1900 |
All |
18 Years and older (Adult, Senior) |
NCT01674140 |
S1207 U10CA032102 NCI-2012-01995 |
e3 |
April 2013 |
December 2022 |
January 2030 |
August 28, 2012 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1432 more...)
|
47 |
NCT03175224 |
Recruiting |
CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation |
- Solid Tumor
- Advanced Cancer
- Renal Cancer
- (and 2 more...)
|
- Drug: CBT-101 Oral Capsules
|
Interventional |
Phase 1 |
- CBT Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03)
- Determine the recommended Phase 2 dose and schedule
- Area under the plasma concentration versus time curve (AUC)
- (and 5 more...)
|
68 |
All |
18 Years and older (Adult, Senior) |
NCT03175224 |
CBT-101-01 |
|
September 27, 2017 |
June 2018 |
June 2019 |
June 5, 2017 |
December 22, 2017 |
|
- Mayo Clinic
Phoenix, Arizona, United States - University of Southern California / Norris Comprehensive Cancer Center
Los Angeles, California, United States - Mayo Clinic
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
48 |
NCT01863550 |
Recruiting |
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Bortezomib
- Drug: Carfilzomib
- Drug: Dexamethasone
- (and 3 more...)
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) for the maintenance analysis
- Progression-free survival for the induction analysis
- Change in the FACT-Ntx TOI for the early induction analysis
- (and 16 more...)
|
1080 |
All |
18 Years and older (Adult, Senior) |
NCT01863550 |
E1A11 NCI-2012-02608 ECOG-E1A11 s17-00040 U10CA180820 U10CA021115 U24CA196172 |
|
December 2, 2013 |
November 1, 2023 |
|
May 29, 2013 |
January 30, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas, United States - Veteran's Administration Medical Center
Little Rock, Arkansas, United States - (and 843 more...)
|
49 |
NCT02893930 |
Recruiting |
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery |
- Pancreatic Neuroendocrine Tumor G1
- Pancreatic Neuroendocrine Tumor G2
- Refractory Pancreatic Neuroendocrine Carcinoma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response (complete response + partial response) as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Progression-free survival (PFS)
- Incidence of adverse events
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02893930 |
NCI-2016-01356 EA2161 U10CA180820 |
|
February 1, 2017 |
August 1, 2019 |
August 1, 2019 |
September 9, 2016 |
April 17, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States - (and 351 more...)
|
50 |
NCT02921256 |
Recruiting |
Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
|
- Drug: Capecitabine
- Drug: Fluorouracil
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in NAR score
- OS
- DFS
- (and 11 more...)
|
174 |
All |
18 Years and older (Adult, Senior) |
NCT02921256 |
NCI-2016-00222 NRG-GI002 s17-00197 U10CA180868 |
|
October 12, 2016 |
April 30, 2019 |
|
October 3, 2016 |
April 13, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 515 more...)
|